Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
2'-deoxyadenosine-3'-fluoro-3'-triphosphate + 2'-deoxyguanosine
2'-deoxyadenosine-3'-fluoro-3'-diphosphate + 2'-deoxyguanosine 5'-phosphate
-
-
-
-
?
2'-deoxyadenosine-3'-fluoroara-3'-triphosphate + 2'-deoxyguanosine
2'-deoxyadenosine-3'-fluoroara-3'-diphosphate + 2'-deoxyguanosine 5'-phosphate
-
low activity
-
-
?
2'-deoxyadenosine-3'-triphosphate + 2'-deoxyguanosine
2'-deoxyadenosine-3'-diphosphate + 2'-deoxyguanosine 5'-phosphate
-
-
-
-
?
3'-deoxyadenosine-2'-triphosphate + 2'-deoxyguanosine
3'-deoxyadenosine-2'-diphosphate + 2'-deoxyguanosine 5'-phosphate
-
-
-
-
?
3'-deoxyadenosine-3'-fluoro-2'-triphosphate + 2'-deoxyguanosine
3'-deoxyadenosine-3'-fluoro-2'-diphosphate + 2'-deoxyguanosine 5'-phosphate
-
-
-
-
?
3'-deoxyadenosine-3'-fluoroxylo-2'-triphosphate + 2'-deoxyguanosine
3'-deoxyadenosine-3'-fluoroxylo-2'-diphosphate + 2'-deoxyguanosine 5'-phosphate
-
-
-
-
?
ATP + 1-(2-deoxy-beta-D-ribofuranosyl)-7-iodoisocarbostyril
ADP + ?
-
4.4% of the activity with 2'-deoxyguanosine
-
-
?
ATP + 1-(2-deoxy-beta-D-ribofuranosyl)-isocarbostyril
ADP + ?
-
poor substrate, 1.1% of the activity with 2'-deoxyguanosine
-
-
?
ATP + 1-beta-D-arabinofuranosyladenine
ADP + 1-beta-D-arabinofuranosyladenine 5'-phosphate
-
-
-
?
ATP + 2',2'-difluorodeoxyguanosine
ADP + 2',2'-difluorodeoxyguanosine 5'-monophosphate
recombinant mitochondrial deoxyguanosine kinase, 147% of activity with deoxyguanosine
-
?
ATP + 2',2'-difluorodeoxyguanosine
ADP + 2',2'-difluorodeoxyguanosine 5'-phosphate
-
-
-
?
ATP + 2',3'-dideoxyguanosine
ADP + 2',3'-dideoxyguanosine 5'-monophosphate
-
recombinant deoxyguanosine kinase, 14% of activity with deoxyguanosine
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
ATP + 2'-deoxyinosine
ADP + 2'-deoxyinosine 5'-phosphate
-
-
-
?
ATP + 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine
ADP + 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine 5'-monophosphate
-
recombinant mitochondrial deoxyguanosine kinase
-
?
ATP + 2-chloro-2'-arabinofluoro-2'-deoxyadenosine
ADP + 2-chloro-2'-arabinofluoro-2'-deoxyadenosine 5'-phosphate
-
-
-
?
ATP + 2-chloro-2'-deoxyadenosine
ADP + 2-chloro-2'-deoxyadenosine monophosphate
ATP + 2-chlorodeoxyadenosine
ADP + 2-chlorodeoxyadenosine 5'-monophosphate
-
-
-
-
?
ATP + 2-chlorodeoxyadenosine
ADP + 2-chlorodeoxyadenosine 5'-phosphate
-
-
-
?
ATP + 2-fluoro-arabinosyl-adenine
ADP + 2-fluoro-arabinosyl-adenine 5'-monophosphate
-
recombinant mitochondrial deoxyguanosine kinase
-
?
ATP + 2-fluoroadenine-beta-D-arabinofuranoside
ADP + 2-fluoroadenine-beta-D-arabinofuranoside 5'-monophosphate
-
-
-
-
?
ATP + 3'-fluoro-2',3'-dideoxyguanosine
ADP + 3'-fluoro-2',3'-dideoxyguanosine 5'-monophosphate
-
recombinant deoxyguanosine kinase, 14% of activity with deoxyguanosine
-
?
ATP + 9-(1,3-dihydroxy-2-propoxymethyl)guanine
ADP + 9-(1,3-dihydroxy-2-propoxymethyl)guanine 5'-monophosphate
-
antiherpesvirus drug ganciclovir, recombinant mitochondrial deoxyguanosine kinase, 6% of activity with deoxyguanosine
-
?
ATP + 9-(4-hydroxy-3-hydroxymethylbutyl-1-yl)guanine
ADP + 9-(4-hydroxy-3-hydroxymethylbutyl-1-yl)guanine 5'-monophosphate
-
antiherpesvirus drug penciclovir, recombinant mitochondrial deoxyguanosine kinase, 50% of activity with deoxyguanosine
-
?
ATP + 9-beta-D-arabinofuranosylguanine
ADP + 9-beta-D-arabinofuranosylguanine 5'-monophosphate
ATP + 9-beta-D-arabinofuranosylguanine
ADP + 9-beta-D-arabinofuranosylguanine 5'-phosphate
-
-
-
?
ATP + 9-beta-D-arabinosylguanine
ADP + 9-beta-D-arabinosylguanine 5'-monophosphate
-
-
-
?
ATP + arabinosyl adenine
ADP + arabinosyl adenine 5'-monophosphate
-
recombinant mitochondrial deoxyguanosine kinase, very low activity
-
?
ATP + arabinosyl guanine
ADP + arabinosyl guanine 5'-monophosphate
-
recombinant mitochondrial deoxyguanosine kinase, better substrate than deoxyguanosine kinase
-
?
ATP + cytarabine
ADP + cytarabine 5'-monophosphate
-
-
-
-
?
ATP + deoxyadenosine
ADP + dAMP
ATP + deoxycytidine
ADP + dCMP
ATP + deoxyguanosine
ADP + dGMP
ATP + deoxyinosine
ADP + dIMP
ATP + deoxythymidine
ADP + dTMP
lowest activity
-
-
?
ATP + deoxyuridine
ADP + dUMP
-
-
-
?
ATP + dideoxyinosine
ADP + dideoxyinosine 5'-monophosphate
-
recombinant mitochondrial deoxyguanosine kinase, very low activity
-
?
ATP + dioxolane guanosine
ADP + dioxolane guanosine 5'-phosphate
ATP + ganciclovir
ADP + ganciclovir phosphate
i.e. 9-(1,3-dihydroxy-2-propoxymethyl)-guanine, low activity
-
-
?
ATP + guanosine
ADP + GMP
ATP + penciclovir
ADP + penciclovir 5'-phosphate
i.e. 9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-guanine, low activity
-
-
?
CTP + 2'-deoxyguanosine
CDP + 2'-deoxyguanosine 5'-phosphate
-
-
-
-
?
CTP + deoxyguanosine
CDP + dGMP
dCTP + deoxyguanosine
dCDP + dGMP
dTTP + deoxyguanosine
?
-
-
-
-
?
dTTP + deoxyguanosine
dTDP + dGMP
dUTP + deoxyguanosine
dUDP + dGMP
-
69% of activity with ATP at pH 6.0, 1.7fold higher activity than with ATP at pH 7.0
-
?
GTP + 2'-deoxyadenosine
GDP + 2'-deoxyadenosine 5'-phosphate
-
very low activity
-
-
?
GTP + 2'-deoxycytidine
GDP + 2'-deoxycytidine 5'-phosphate
-
very low activity
-
-
?
GTP + 2'-deoxyguanosine
GDP + 2'-deoxyguanosine 5'-phosphate
-
-
-
-
?
GTP + 2'-deoxyinosine
GDP + 2'-deoxyinosine 5'-phosphate
-
-
-
-
?
GTP + deoxyguanosine
GDP + dGMP
-
50% of activity with ATP
-
?
GTP + guanosine
GDP + guanosine 5'-phosphate
-
very low activity
-
-
?
triphosphate + 2'-deoxyguanosine
diphosphate + 2'-deoxyguanosine 5'-phosphate
-
triphosphate is active with 2'deoxyguanosine, 50% of the activity with ATP
-
-
?
UTP + 2'-deoxyadenosine
UDP + 2'-deoxyadenosine 5'-phosphate
-
-
-
?
UTP + 2'-deoxyguanosine
UDP + 2'-deoxyguanosine 5'-phosphate
UTP + 2'-deoxyinosine
UDP + 2'-deoxyinosine 5'-phosphate
-
-
-
?
UTP + 9-beta-D-arabinofuranosylguanine
UDP + 9-beta-D-arabinofuranosylguanine 5'-phosphate
i.e. nelarabine, activation of the anticancer drug
-
-
?
UTP + deoxyguanosine
UDP + dGMP
additional information
?
-
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
key enzyme in mitochondrial DNA precursor synthesis
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
-
-
-
ir
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
key enzyme in mitochondrial DNA precursor synthesis
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
important enzyme for the phosphorylation/activation of 2'-deoxyguanosine
-
-
ir
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
one of the two mitochondrial deoxynucleoside salvage pathway enzymes involved in precursor synthesis for mitochondrial DNA replication, DGUOK is responsible for the initial rate-limiting phosphorylation of the purine deoxynucleosides, mutations of the enzyme are associated with the hepato-specific and hepatocerebral forms of the mtDNA depletion syndrome
-
-
?
ATP + 2-chloro-2'-deoxyadenosine
ADP + 2-chloro-2'-deoxyadenosine monophosphate
-
-
-
?
ATP + 2-chloro-2'-deoxyadenosine
ADP + 2-chloro-2'-deoxyadenosine monophosphate
-
recombinant mitochondrial deoxyguanosine kinase
-
?
ATP + 2-chloro-2'-deoxyadenosine
ADP + 2-chloro-2'-deoxyadenosine monophosphate
recombinant mitochondrial deoxyguanosine kinase, 200% of activity with deoxyguanosine at 0.005 mM
-
?
ATP + 9-beta-D-arabinofuranosylguanine
ADP + 9-beta-D-arabinofuranosylguanine 5'-monophosphate
-
-
-
-
?
ATP + 9-beta-D-arabinofuranosylguanine
ADP + 9-beta-D-arabinofuranosylguanine 5'-monophosphate
-
guanosine analog with activity in patients with T-cell malignancies
-
?
ATP + deoxyadenosine
ADP + dAMP
-
3% of activity with deoxyguanosine
-
-
?
ATP + deoxyadenosine
ADP + dAMP
barely measurable phosphorylation of deoxyadenosine
-
-
?
ATP + deoxyadenosine
ADP + dAMP
-
recombinant mitochondrial deoxyguanosine kinase
-
?
ATP + deoxyadenosine
ADP + dAMP
-
4.8%, 25.8% and 93.5% of activity with deoxyguanosine at 0.01 mM, 0.1 mM and 1 mM deoxyguanosine, respectively
-
?
ATP + deoxyadenosine
ADP + dAMP
recombinant mitochondrial deoxyguanosine kinase, very low activity
-
?
ATP + deoxyadenosine
ADP + dAMP
-
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
recombinant deoxyguanosine kinase, 3% of activity with deoxyguanosine
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
-
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
recombinant mitochondrial deoxyguanosine kinase
-
?
ATP + deoxycytidine
ADP + dCMP
-
-
-
?
ATP + deoxyguanosine
ADP + dGMP
-
-
-
?
ATP + deoxyguanosine
ADP + dGMP
-
-
-
?
ATP + deoxyguanosine
ADP + dGMP
-
no activity with deoxycytidine
-
?
ATP + deoxyguanosine
ADP + dGMP
-
no activity with deoxycytidine
-
?
ATP + deoxyguanosine
ADP + dGMP
-
poor donor substrates are dATP or GTP
-
?
ATP + deoxyguanosine
ADP + dGMP
-
no activity with inosine and 9-beta-arabinofuranosyladenine
-
?
ATP + deoxyguanosine
ADP + dGMP
-
no activity with deoxythymidine, uridine and cytosine
-
?
ATP + deoxyguanosine
ADP + dGMP
-
no activity with dGTP
-
?
ATP + deoxyguanosine
ADP + dGMP
-
ATP most efficient at pH 5.5, dTTP or UTP most efficient, i.e. more efficient than ATP, at pH 7.4
-
?
ATP + deoxyguanosine
ADP + dGMP
-
no activity with dITP
-
?
ATP + deoxyguanosine
ADP + dGMP
-
no activity with adenosine
-
?
ATP + deoxyguanosine
ADP + dGMP
-
no activity with adenosine
-
?
ATP + deoxyguanosine
ADP + dGMP
-
ATP can be replaced by dTTP, CTP, dCTP and UTP
-
?
ATP + deoxyguanosine
ADP + dGMP
-
highly specific for phospho group acceptor
-
?
ATP + deoxyguanosine
ADP + dGMP
-
enzyme of purine deoxynucleoside salvage pathway
-
?
ATP + deoxyguanosine
ADP + dGMP
-
-
-
?
ATP + deoxyguanosine
ADP + dGMP
-
-
-
-
?
ATP + deoxyguanosine
ADP + dGMP
-
-
-
?
ATP + deoxyguanosine
ADP + dGMP
-
no activity with deoxycytidine
-
?
ATP + deoxyguanosine
ADP + dGMP
-
ATP can be replaced by dUTP
-
?
ATP + deoxyguanosine
ADP + dGMP
-
no activity with dATP and GTP
-
?
ATP + deoxyguanosine
ADP + dGMP
-
no activity with dGTP
-
?
ATP + deoxyguanosine
ADP + dGMP
-
recombinant mitochondrial deoxyguanosine kinase does not discriminate between beta-D-2'-deoxyguanosine and beta-L-2'-deoxyguanosine
-
?
ATP + deoxyguanosine
ADP + dGMP
-
ATP can be replaced by dTTP, CTP, dCTP and UTP
-
?
ATP + deoxyguanosine
ADP + dGMP
-
-
-
-
?
ATP + deoxyguanosine
ADP + dGMP
-
-
-
?
ATP + deoxyguanosine
ADP + dGMP
-
-
-
?
ATP + deoxyguanosine
ADP + dGMP
-
-
?
ATP + deoxyguanosine
ADP + dGMP
-
no activity with deoxycytidine
-
?
ATP + deoxyguanosine
ADP + dGMP
-
no activity with dATP or GTP
-
?
ATP + deoxyguanosine
ADP + dGMP
-
no activity with deoxythymidine, uridine and cytosine
-
?
ATP + deoxyguanosine
ADP + dGMP
-
no activity with dGTP
-
?
ATP + deoxyguanosine
ADP + dGMP
-
no activity with adenosine
-
?
ATP + deoxyguanosine
ADP + dGMP
-
ATP can be replaced by dTTP, CTP, dCTP and UTP
-
?
ATP + deoxyguanosine
ADP + dGMP
-
84%, 64%, 35% and 20% of activity with ATP with dTTP, CTP, dCTP and UTP, respectively
-
?
ATP + deoxyguanosine
ADP + dGMP
-
first reaction in reutilization of deoxyguanosine for dGTP biosynthesis
-
?
ATP + deoxyguanosine
ADP + dGMP
-
highly specific for phospho group acceptor
-
?
ATP + deoxyguanosine
ADP + dGMP
-
ATP twice as effective as CTP or GTP and 4 times as effective as UTP
-
?
ATP + deoxyguanosine
ADP + dGMP
-
-
-
?
ATP + deoxyguanosine
ADP + dGMP
highest activity
-
-
?
ATP + deoxyinosine
ADP + dIMP
-
63% of activity with deoxyguanosine
-
?
ATP + deoxyinosine
ADP + dIMP
-
-
-
?
ATP + deoxyinosine
ADP + dIMP
-
-
-
-
?
ATP + deoxyinosine
ADP + dIMP
-
recombinant mitochondrial deoxyguanosine kinase
-
?
ATP + deoxyinosine
ADP + dIMP
-
recombinant mitochondrial deoxyguanosine kinase, may be the preferred substrate in vivo
-
?
ATP + deoxyinosine
ADP + dIMP
10% of activity with deoxyguanosine
-
?
ATP + dioxolane guanosine
ADP + dioxolane guanosine 5'-phosphate
-
low activity, step in anabolism of amdoxovir, i.e. (-)-beta-D-2,6-diaminopurine dioxolane, a prodrug of dioxolane guanosine
-
-
?
ATP + dioxolane guanosine
ADP + dioxolane guanosine 5'-phosphate
-
0.02% of the activity with 2'-deoxyguanosine
-
-
?
ATP + guanosine
ADP + GMP
-
recombinant deoxyguanosine kinase, 7% of activity with deoxyguanosine
-
?
ATP + guanosine
ADP + GMP
-
mitochondrial deoxyguanosine kinase
-
?
CTP + deoxyguanosine
CDP + dGMP
-
-
-
?
CTP + deoxyguanosine
CDP + dGMP
-
62% of activity with ATP at pH 6.0, 1.8fold higher activity than with ATP at pH 7.0
-
?
CTP + deoxyguanosine
CDP + dGMP
-
64% of activity with ATP
-
?
CTP + deoxyguanosine
CDP + dGMP
-
50% of activity with ATP
-
-
?
dCTP + deoxyguanosine
dCDP + dGMP
-
-
-
?
dCTP + deoxyguanosine
dCDP + dGMP
-
-
-
?
dCTP + deoxyguanosine
dCDP + dGMP
-
35% of activity with ATP
-
?
dTTP + deoxyguanosine
dTDP + dGMP
-
-
-
?
dTTP + deoxyguanosine
dTDP + dGMP
-
83% of activity with ATP at pH 6.0, 2.8fold higher activity than with ATP at pH 7.0
-
?
dTTP + deoxyguanosine
dTDP + dGMP
-
84% of activity with ATP
-
?
UTP + 2'-deoxyguanosine
UDP + 2'-deoxyguanosine 5'-phosphate
-
preferred substrates
-
-
?
UTP + 2'-deoxyguanosine
UDP + 2'-deoxyguanosine 5'-phosphate
-
-
-
?
UTP + deoxyguanosine
UDP + dGMP
-
-
-
?
UTP + deoxyguanosine
UDP + dGMP
-
-
-
?
UTP + deoxyguanosine
UDP + dGMP
-
20% of activity with ATP
-
?
UTP + deoxyguanosine
UDP + dGMP
-
25% of activity with ATP
-
?
additional information
?
-
-
substrate specificity, the enzyme utilizes all naturally occurring ribo-and deoxyribonucleosides triphosphates, with the exception of dGTP, as phosphate donors, and shows poor activity with thymidine, inosine, adenosine, 2,3-dideoxyguanosine, 2,3-dideoxyinosine, 2,3-dideoxyadenosine, and hypoxanthine arabinoside as acceptor substrates
-
-
?
additional information
?
-
the enzyme has low specificity for guanosine
-
-
?
additional information
?
-
the enzyme has low specificity for guanosine
-
-
?
additional information
?
-
-
no activity with diphosphate as phosphate donor
-
-
?
additional information
?
-
de novo synthesis and salvage of ribonucleotides and deoxyribonucleotides, metabolism overview
-
-
?
additional information
?
-
-
enzyme defect due to genetic alterations leads to tissue-specific mitochondrial DNA depletion causing multi-systemic disease or devastating liver disease
-
-
?
additional information
?
-
-
th enzyme catalyzes the initial phosphorylation of purine deoxynucleosides, enzyme deficiency leads to severe mitochondrial DNA depletion diseases
-
-
?
additional information
?
-
the earliest nucleotide kinase in evolution, probably encoded by the so-called dCK/dGK/TK2-like gene, is the progenitor gene, several duplications of it are the reason for evolutionary occurring of nucleoside kinases with strict substrate specificities in other organism, phylogenetic tree, overview
-
-
?
additional information
?
-
anticancer drugs 2-chloro-2'-deoxyadenosine, i.e. cladribine, and 2-fluoro-9-beta-D-arabinofuranosyladenine, i.e. clofarabine, are poor substrates
-
-
?
additional information
?
-
-
no activity with several difluorophenyl nucleoside analogues, overview
-
-
?
additional information
?
-
substrate interactions, overview, enzyme shows relaxed enantioselectivity, accepting D- and L-enantiomers of beta-deoxyguanosine but with lower activity than alpha-L-deoxyguanosine, and beta-L-deoxyadenosine, enzyme accepts purine deoxynucleosides and analogues as substrates utilizing a triphosphate donor substrate
-
-
?
additional information
?
-
the enzyme is highly specific for purine substrates, Arg118 is responsible for the substrate specificity
-
-
?
additional information
?
-
-
the enzyme is highly specific for purine substrates, Arg118 is responsible for the substrate specificity
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.019
1-(2-deoxy-beta-D-ribofuranosyl)-7-iodoisocarbostyril
-
pH 7.6, 37°C, recombinant enzyme
0.0026 - 0.5
2'-deoxyadenosine
0.0006 - 0.123
2'-deoxyguanosine
0.056
2-chloro-2'-arabino-fluoro-2'-deoxyadenosine
-
pH 7.6, recombinant mitochondrial deoxyguanosine kinase
0.078
2-chloro-2'-deoxyadenosine
-
pH 7.6, recombinant mitochondrial deoxyguanosine kinase
0.008 - 0.062
2-chlorodeoxyadenosine
0.46
2-fluoro-arabinosyl-adenine
-
pH 7.6, recombinant mitochondrial deoxyguanosine kinase
0.033
arabinosyl guanine
-
pH 7.6, recombinant mitochondrial deoxyguanosine kinase
0.206 - 2.689
deoxyadenosine
0.34 - 4.424
deoxycytidine
0.00032 - 0.76
deoxyguanosine
0.012 - 0.021
deoxyinosine
201.859
deoxythymidine
at pH 8.0, temperature not specified in the publication
10.624
deoxyuridine
at pH 8.0, temperature not specified in the publication
7
dioxolane guanosine
-
recombinant enzyme, pH 7.6, 37°C
0.092
Triphosphate
-
pH 7.5, 37°C
additional information
additional information
-
0.0026
2'-deoxyadenosine
-
patient with double mutation N46S/L266, pH 7.4, 37°C
0.0035
2'-deoxyadenosine
-
father (L266R), pH 7.4, 37°C
0.0041
2'-deoxyadenosine
-
brother (N46S), pH 7.4, 37°C
0.0053
2'-deoxyadenosine
-
mother (N46S), pH 7.4, 37°C
0.0068
2'-deoxyadenosine
-
control group, pH 7.4, 37°C
0.414
2'-deoxyadenosine
-
pH 7.6, recombinant mutant E227K
0.467
2'-deoxyadenosine
-
pH 7.6, wild-type enzyme
0.467
2'-deoxyadenosine
-
pH 7.6, recombinant wild-type enzyme
0.5
2'-deoxyadenosine
-
pH 7.6, mutant L250S
0.0006
2'-deoxyguanosine
-
pH 8.5, 37°C, cosubstrate UTP
0.0006
2'-deoxyguanosine
-
pH 8.5, 37°C, recombinant enzyme, with UTP as donor substrate
0.0017
2'-deoxyguanosine
-
recombinant enzyme, pH 7.6, 37°C
0.0017
2'-deoxyguanosine
-
pH 8.5, 37°C, recombinant enzyme, with CTP as donor substrate
0.0018
2'-deoxyguanosine
-
control group, pH 7.4, 37°C
0.0019
2'-deoxyguanosine
-
brother (N46S), pH 7.4, 37°C
0.002
2'-deoxyguanosine
-
pH 7.6, 37°C, recombinant enzyme
0.0023
2'-deoxyguanosine
-
father (L266R), pH 7.4, 37°C
0.0028
2'-deoxyguanosine
-
mother (N46S), pH 7.4, 37°C
0.0034
2'-deoxyguanosine
-
patient with double mutation N46S/L266, pH 7.4, 37°C
0.004
2'-deoxyguanosine
-
pH 7.6, wild-type enzyme
0.004
2'-deoxyguanosine
-
pH 7.6, recombinant wild-type enzyme
0.0052
2'-deoxyguanosine
-
pH 7.6, recombinant mutant E227K
0.0065
2'-deoxyguanosine
-
pH 8.5, 37°C, cosubstrate ATP
0.0065
2'-deoxyguanosine
-
pH 8.5, 37°C, recombinant enzyme, with ATP as donor substrate
0.01
2'-deoxyguanosine
-
pH 8.5, 37°C, cosubstrate GTP
0.0104
2'-deoxyguanosine
-
pH 8.5, 37°C, recombinant enzyme, with GTP as donor substrate
0.017
2'-deoxyguanosine
-
pH 8.5, 37°C, cosubstrate CTP
0.023
2'-deoxyguanosine
-
pH 7.6, mutant L250S
0.123
2'-deoxyguanosine
-
pH 7.6, recombinant mutant R142K
0.008
2-chlorodeoxyadenosine
-
pH 7.6, 37°C, recombinant deoxguanosine kinase, cosubstrate UTP
0.062
2-chlorodeoxyadenosine
-
pH 7.6, 37°C, recombinant deoxguanosine kinase, cosubstrate ATP
0.0085
ATP
-
pH 7.6, recombinant wild-type enzyme, with 2'-deoxyguanosine
0.0085
ATP
-
pH 7.6, wild-type enzyme, with 2'-deoxyguanosine
0.014
ATP
-
pH 7.6, recombinant mutant E227K, with 2'-deoxyguanosine
0.023
ATP
-
pH 5.2, 37°C, at concentrations below 0.5 mM
0.023
ATP
-
ATP in form of MgATP2-
0.034
ATP
-
pH 7.6, mutant L250S, with 2'-deoxyguanosine
0.036
ATP
-
pH 8.5, 37°C, recombinant enzyme, with 2'-deoxyguanosine as acceptor substrate
0.0974
ATP
-
pH 7.6, recombinant mutant R142K, with 2'-deoxyguanosine
0.13
ATP
-
ATP in form of MgATP2-
0.242
ATP
-
pH 7.6, recombinant mutant E227K, with 2'-deoxyadenosine
0.269
ATP
-
pH 7.6, recombinant wild-type enzyme, with 2'-deoxyadenosine
0.269
ATP
-
pH 7.6, wild-type enzyme, with 2'-deoxyadenosine
0.302
ATP
-
pH 7.6, mutant L250S, with 2'-deoxyadenosine
0.63
ATP
-
pH 5.2, 37°C, at concentrations above 0.5 mM
0.63
ATP
-
ATP in form of MgATP2-
0.78
ATP
-
pH 7.4, 37°C, mitochondrial deoxyguanosine kinase
3.3
ATP
-
ATP in form of MgATP2-
0.035
CTP
-
pH 8.5, 37°C
0.035
CTP
-
pH 8.5, 37°C, recombinant enzyme, with 2'-deoxyguanosine as acceptor substrate
0.206
deoxyadenosine
-
0.47
deoxyadenosine
-
pH 7.6, recombinant mitochondrial deoxyguanosine kinase
0.63
deoxyadenosine
-
pH 6.0, 37°C
2.689
deoxyadenosine
at pH 8.0, temperature not specified in the publication
0.34
deoxycytidine
-
pH 7.6, recombinant mitochondrial deoxyguanosine kinase
4.424
deoxycytidine
at pH 8.0, temperature not specified in the publication
0.00032
deoxyguanosine
-
pH 8.0, 37°C
0.0005
deoxyguanosine
at pH 8.0, temperature not specified in the publication
0.0025
deoxyguanosine
-
pH 6.0, 37°C
0.0028
deoxyguanosine
-
pH 7.6, 37°C, recombinant deoxguanosine kinase, cosubstrate ATP
0.0037
deoxyguanosine
-
pH 7.6, 37°C, recombinant deoxguanosine kinase, cosubstrate UTP
0.004
deoxyguanosine
-
pH 7.6, recombinant mitochondrial deoxyguanosine kinase
0.0047
deoxyguanosine
-
-
0.0047
deoxyguanosine
-
pH 7.4, 37°C, mitochondrial deoxyguanosine kinase
0.006
deoxyguanosine
-
pH 7.5, 37°C, mitochondrial deoxyguanosine kinase
0.007
deoxyguanosine
-
pH 5.2, 37°C
0.065
deoxyguanosine
-
pH 8.0, 20°C
0.087
deoxyguanosine
pH 8.0, 20°C
0.34
deoxyguanosine
pH 8.0, 20°C, D84N mutant enzyme
0.36
deoxyguanosine
pH 8.0, 20°C, D84A mutant enzyme
0.55
deoxyguanosine
pH 8.0, 20°C, D84E mutant enzyme
0.76
deoxyguanosine
-
pH 8.0, 20°C, R79K mutant enzyme
0.012
deoxyinosine
-
pH 7.6, recombinant mitochondrial deoxyguanosine kinase
0.021
deoxyinosine
-
pH 7.4, 37°C, mitochondrial deoxyguanosine kinase
0.08
dTTP
-
pH 7.4, 37°C, mitochondrial deoxyguanosine kinase
2.2
dTTP
-
dTTP in form of MgdTTP2-
0.046
GTP
-
pH 8.5, 37°C
0.046
GTP
-
pH 8.5, 37°C, recombinant enzyme, with 2'-deoxyguanosine as acceptor substrate
0.006
UTP
-
pH 8.5, 37°C
0.006
UTP
-
pH 8.5, 37°C, recombinant enzyme, with 2'-deoxyguanosine as acceptor substrate
0.125
UTP
-
pH 7.4, 37°C, mitochondrial deoxyguanosine kinase
additional information
additional information
-
reaction of the mutant L250S with 2'-deoxyguanosine follows Michaelis-Menten kinetics, while the reaction with 2'-deoxyadenosine shows biphasic kinetics
-
additional information
additional information
-
the reaction with triphosphate follows strict Michaelis-Menten kinetics, while ATP exhibits negative cooperativity
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.117
1-alpha-D-arabinofuranosylguanine
-
pH 7.4, 37°C, competitive vs. deoxyguanosine, mitochondrial deoxyguanosine kinase
0.43
8-aza-2'-deoxyguanosine
-
pH 7.4, 37°C, competitive vs. deoxyguanosine, mitochondrial deoxyguanosine kinase
1
ADP
-
pH 7.4, 37°C, noncompetitive vs. deoxyguanosine, mitochondrial deoxyguanosine kinase
0.028
dAMP
-
pH 7.6, 37°C, recombinant deoxyguanosine kinase
0.041
dATP
-
pH 7.6, 37°C, recombinant deoxyguanosine kinase
0.34
deoxyadenosine
-
pH 8.0, 37°C
0.075
deoxyinosine
-
pH 7.4, 37°C, competitive vs. deoxyguanosine, mitochondrial deoxyguanosine kinase
additional information
additional information
-
product inhibition of the enzyme, overview
-
0.00052
dGDP
-
pH 7.4, 37°C, vs. ATP, mitochondrial deoxyguanosine kinase
0.0007
dGDP
-
pH 5.2, 37°C, competitive vs. MgATP2-, at MgATP2- concentrations above 0.5 mM
0.0087
dGDP
-
pH 7.4, 37°C, vs. deoxyguanosine, mitochondrial deoxyguanosine kinase
0.004
dGMP
-
pH 7.6, 37°C, recombinant deoxyguanosine kinase
0.0058
dGMP
-
pH 7.4, 37°C, vs. ATP mitochondrial deoxyguanosine kinase
0.009
dGMP
-
pH 7.4, 37°C, vs. dTTP, mitochondrial deoxyguanosine kinase
0.076
dGMP
-
pH 8.0, 37°C
0.1
dGMP
-
pH 7.4, 37°C, vs. deoxyguanosine, mitochondrial deoxyguanosine kinase
0.18
dGMP
-
pH 5.2, 37°C, competitive vs. deoxyguanosine
0.25
dGMP
-
pH 7.4, 37°C, vs.ATP, mitochondrial deoxyguanosine kinase
0.00003
dGTP
-
pH 7.4, 37°C, vs. ATP, mitochondrial deoxyguanosine kinase
0.00007
dGTP
-
pH 5.2, 37°C, competitive vs. MgATP2-, at MgATP2- concentrations above 0.5 mM
0.0004
dGTP
-
pH 7.6, 37°C, recombinant deoxyguanosine kinase
0.00093
dGTP
-
pH 7.4, 37°C, vs. deoxyguanosine, mitochondrial deoxyguanosine kinase
0.0019
dGTP
-
pH 5.2, 37°C, competitive vs. deoxyguanosine
0.0019
dGTP
-
pH 8.0, 20°C, vs. ATP
0.00333
dGTP
-
pH 8.0, 20°C, vs. deoxyguanosine
0.021
dGTP
-
pH 8.0, 37°C
0.031
dIMP
-
pH 7.4, 37°C, vs. ATP, mitochondrial deoxyguanosine kinase
0.078
dIMP
-
pH 7.6, 37°C, recombinant deoxyguanosine kinase
0.098
dIMP
-
pH 7.4, 37°C, vs. deoxyguanosine, mitochondrial deoxyguanosine kinase
0.0001
dITP
-
pH 7.4, 37°C, vs. ATP, mitochondrial deoxyguanosine kinase
0.0026
dITP
-
pH 7.4, 37°C, vs. deoxyguanosine, mitochondrial deoxyguanosine kinase
0.21
dTDP
-
pH 7.4, 37°C, vs. ATP, mitochondrial deoxyguanosine kinase
0.39
dTDP
-
pH 7.4, 37°C, vs. deoxyguanosine, mitochondrial deoxyguanosine kinase
0.73
dTDP
-
pH 7.4, 37°C, vs. dTTP, mitochondrial deoxyguanosine kinase
0.003
UDP
-
pH 5.2, 37°C, competitive vs. MgATP2-, at MgATP2- concentrations above 0.5 mM
0.063
UDP
-
pH 8.5, 37°C, cosubstrate UTP
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
A2S
-
resulting from a base change G to T at position 4, a G base change immediately after the start codon is likely to affect start codon recognition by the ribosome the patient has an additional base change G to A at position 591 results in skipping of exon 4, very low residual activity
D255Y/D255Y
-
the mutation is associated with deoxyguanosine kinase deficiency
E165V
-
naturally occuring enzyme mutation involved in mitochondrial depletion syndrome
E227K
-
site-directed mutagenesis, mutation is naturally found in patients, unaltered Km but very low Vmax for all substrates compared to the wild-type enzyme
F256X
-
naturally occuring enzyme mutation involved in mitochondrial depletion syndrome
H226R
the mutation is associated with a clinical phenotype that consists of neonatal liver failure, nystagmus and hypotonia
I43T
the mutation is associated with infantile mitochondrial DNA depletion syndrome
K51Q
the p.K51Q alteration changes the basic amino acid lysine to the uncharged polar amino acid glutamine in the ATP binding site and is expected to interfere with enzymatic function, the mutation is associated with a clinical phenotype that consists of neonatal liver failure, nystagmus and hypotonia
L250S
-
naturally occurring mutation in a patient with mitochondrial DNA depletion syndrome, patient shows rapidly progressing, early onset fatal liver failure associated with profoundly decreased mtDNA levels in liver and, to a lesser extent, in skeletal muscle, mutation is introduced into the enzyme cDNA via site-directed mutagenesis, the mutant enzyme shows 0.5% remaining activity compared to the wild-type enzyme
L250S/M1T
-
the mutation is associated with deoxyguanosine kinase deficiency
M1I
-
naturally occuring enzyme mutation involved in mitochondrial depletion syndrome
M1V/M1I
-
the mutation is associated with deoxyguanosine kinase deficiency
R105*
the mutation is associated with infantile mitochondrial DNA depletion syndrome
R118C
the mutation is associated with a clinical phenotype that consists of neonatal liver failure, nystagmus and hypotonia
R142K
-
site-directed mutagenesis, mutation is naturally found in patients, low activity with dG, no activity with dA compared to the wild-type enzyme
R142K/E227K
-
the mutation is associated with deoxyguanosine kinase deficiency
S52F/S52F
-
the mutation is associated with deoxyguanosine kinase deficiency
W178X
the mutation is associated with a clinical phenotype that consists of neonatal liver failure, nystagmus and hypotonia
W65X
the mutation is associated with a clinical phenotype that consists of neonatal liver failure, nystagmus and hypotonia
Y191C
the mutation is associated with a clinical phenotype that consists of neonatal liver failure, nystagmus and hypotonia
D78A
-
no deoxyguanosine kinase activity
D78E
-
no deoxyguanosine kinase activity
D78N
-
no deoxyguanosine kinase activity
R79k
-
50% of wild-type deoxyguanosine kinase activity
D84A
1% of wild-type activity
D84E
41% of wild-type activity, not inhibited by dGTP and dATP
D84N
5% of wild-type activity
D84A
-
1% of wild-type activity
-
D84E
-
41% of wild-type activity, not inhibited by dGTP and dATP
-
D84N
-
5% of wild-type activity
-
L266R
-
10% residual activity
L266R
-
father of patient with double mutant, 42 of the mean control value for 2'-deoxyguanosine, and 41 of the mean control value for 2'-deoxyadenosine
N46S
-
14% residual activity
N46S
-
mother and brother of patient with double mutant, 61 and 45% of the mean control value for 2'-deoxyguanosine, and 59 and 44% of the mean control value for 2'-deoxyadenosine
N46S
the mutation is associated with a clinical phenotype that consists of neonatal liver failure, nystagmus and hypotonia
N46S
the mutation is associated with familial idiopathic noncirrhotic portal hypertension
N46S/L266R
-
naturally occuring mutation, 14 and 10% residual activity as compared with controls with deoxyguanosine and deoxyadenosine, patient shows improved liver tests starting from age 46 month, at age 10 years clinically healthy
N46S/L266R
-
the mutation is associated with deoxyguanosine kinase deficiency
additional information
-
C-terminally truncated mutants are catalytically inactive, naturally occuring genetic defects/mutations, overview
additional information
-
duplication of bases 763 to 766 in exon 6 results in a truncated non-functional protein, very low residual activity
additional information
frame shift mutation c.80delC causes a truncated polypeptide of 64 amino acids and frame shift mutation c763_c766dupGATT results in a truncated polypeptide of 256 amino acids, the c.591G>A nucleotide substitution, located at the end of exon 4 does not result in amino acid change (p.Q197Q), but it changes the consensus splice site sequence, this is predicted to result in aberrant splicing, the frame shift mutation c.605_c.606delGA produces a premature stop codon and a truncated protein of 214 amino acids
additional information
-
frame shift mutation c.80delC causes a truncated polypeptide of 64 amino acids and frame shift mutation c763_c766dupGATT results in a truncated polypeptide of 256 amino acids, the c.591G>A nucleotide substitution, located at the end of exon 4 does not result in amino acid change (p.Q197Q), but it changes the consensus splice site sequence, this is predicted to result in aberrant splicing, the frame shift mutation c.605_c.606delGA produces a premature stop codon and a truncated protein of 214 amino acids
additional information
-
identification of deoxyguanosine kinase gene mutations. Most frequent mutation identified in patients with liver pathology is the c.3G>A substitution in the DGUOK exon 1, potentially causing a severe impairment in the synthesis of the protein, geno-y and phenotypes, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Barker, J.; Lewis, R.A.
Deoxyguanosine kinase of neonatal mouse skin tissue
Biochim. Biophys. Acta
658
111-123
1981
Mus musculus
brenda
Gower, W.R.; Carr, M.C.; Ives, D.H.
Deoxyguanosine kinase. Distinct molecular forms in mitochondria and cytosol
J. Biol. Chem.
254
2180-2183
1979
Bos taurus
brenda
Park, I.; Ives, D.H.
Properties of a highly purified mitochondrial deoxyguanosine kinase
Arch. Biochem. Biophys.
266
51-60
1988
Bos taurus
brenda
Green, F.J.; Lewis, R.A.
Partial purification and characterization of deoxyguanosine kinase from pig skin
Biochem. J.
183
547-553
1979
Sus scrofa
brenda
Yamada, Y.; Goto, H.; Ogasawara, N.
Deoxyguanosine kinase from human placenta
Biochim. Biophys. Acta
709
265-272
1982
Homo sapiens
brenda
Park, I.; Ives, D.H.
Kinetic mechanism and end-product regulation of deoxyguanosine kinase from beef liver mitochondria
J. Biochem.
117
1058-1061
1995
Bos taurus
brenda
Sjoberg, A.H.; Wang, L.; Eriksson, S.
Substrate specificity of human recombinant mitochondrial deoxyguanosine kinase with cytostatic and antiviral purine and pyrimidine analogs
Mol. Pharmacol.
53
270-273
1998
Homo sapiens
brenda
Zhu, C.; Johansson, M.; Permert, J.; Karlsson, A.
Enhanced cytotoxicity of nucleoside analogs by overexpression of mitochondrial deoxyguanosine kinase in cancer cell lines
J. Biol. Chem.
273
14707-14711
1998
Homo sapiens
brenda
Gaubert, G.; Gosselin, G.; Boudou, V.; Imbach, J.L.; Eriksson, S.; Maury, G.
Low enantioselectivities of human deoxycytidine kinase and human deoxyguanosine kinase with respect to 2'-deoxyadenosine, 2'-deoxyguanosine and their analogs
Biochimie
81
1041-1047
1999
Homo sapiens
brenda
Petrakis, T.G.; Ktistaki, E.; Wang, L.; Eriksson, S.; Talianidis, I.
Cloning and characterization of mouse deoxyguanosine kinase. Evidence for a cytoplasmic isoform
J. Biol. Chem.
274
24726-24730
1999
Mus musculus (Q9QX60), Mus musculus
brenda
Jullig, M.; Eriksson, S.
Mitochondrial and submitochondrial localization of human deoxyguanosine kinase
Eur. J. Biochem.
267
5466-5472
2000
Homo sapiens
brenda
Jullig, M.; Eriksson, S.
Apoptosis induces efflux of the mitochondrial matrix enzyme deoxyguanosine kinase
J. Biol. Chem.
276
24000-24004
2001
Homo sapiens
brenda
Andersen, R.B.; Neuhard, J.
Deoxynucleoside kinases encoded by the yaaG and yaaF genes of Bacillus subtilis. Substrate specificity and kinetic analysis of deoxyguanosine kinase with UTP as the preferred phosphate donor
J. Biol. Chem.
276
5518-5524
2001
Bacillus subtilis
brenda
Herrstrom Sjoberg, A.; Wang, L.; Eriksson, S.
Antiviral guanosine analogs as substrates for deoxyguanosine kinase: implications for chemotherapy
Antimicrob. Agents Chemother.
45
739-742
2001
Bos taurus, Homo sapiens
brenda
Lotfi, K.; Mansson, E.; Peterson, C.; Eriksson, S.; Albertioni, F.
Low level of mitochondrial deoxyguanosine kinase is the dominant factor in acquired resistance to 9-beta-D-arabinofuranosylguanine cytotoxicity
Biochem. Biophys. Res. Commun.
293
1489-1496
2002
Homo sapiens
brenda
Park, I.; Ives, D.H.
Mutations within the putative active site of heterodimeric deoxyguanosine kinase block the allosteric activation of the deoxyadenosine kinase subunit
J. Biochem. Mol. Biol.
35
244-247
2002
Lactobacillus johnsonii (Q74HC2), Lactobacillus johnsonii NCC 533 (Q74HC2)
brenda
Hong, Y.S.; Ma, G.T.; Ives, D.H.
Directed mutagenesis of deoxyguanosine site at arginine 79 up-regulates turnover on deoxyadenosine kinase subunit of heterodimeric enzyme from Lactobacillus acidophilus R26
J. Biol. Chem.
270
6602-6606
1995
Lactobacillus acidophilus
brenda
Ikeda, S.; Ma, G.T.; Ives, D.H.
Heterodimeric deoxynucleoside kinases of Lactobacillus acidophilus R-26: functional assignment of subunits using limited proteolysis controlled by end-product inhibitors
Biochemistry
33
5328-5334
1994
Lactobacillus acidophilus
brenda
Ma, G.T.; Hong, Y.S.; Ives, D.H.
Cloning and expression of the heterodimeric deoxyguanosine kinase/deoxyadenosine kinase of Lactobacillus acidophilus R-26
J. Biol. Chem.
270
6595-6601
1995
Lactobacillus johnsonii (Q74HC2), Lactobacillus johnsonii NCC 533 (Q74HC2)
brenda
Rodriguez, C.O., Jr.; Mitchell, B.S.; Ayres, M.; Eriksson, S.; Gandhi, V.
Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase
Cancer Res.
62
3100-3105
2002
Homo sapiens
brenda
Krawiec, K.; Kierdaszuk, B.; Shugar, D.
Inorganic tripolyphosphate (PPP(i)) as a phosphate donor for human deoxyribonucleoside kinases
Biochem. Biophys. Res. Commun.
301
192-197
2003
Homo sapiens
brenda
Feng, J.Y.; Parker, W.B.; Krajewski, M.L.; Deville-Bonne, D.; Veron, M.; Krishnan, P.; Cheng, Y.C.; Borroto-Esoda, K.
Anabolism of amdoxovir: phosphorylation of dioxolane guanosine and its 5'-phosphates by mammalian phosphotransferases
Biochem. Pharmacol.
68
1879-1888
2004
Homo sapiens
brenda
Rylova, S.N.; Albertioni, F.; Flygh, G.; Eriksson, S.
Activity profiles of deoxynucleoside kinases and 5'-nucleotidases in cultured adipocytes and myoblastic cells: insights into mitochondrial toxicity of nucleoside analogs
Biochem. Pharmacol.
69
951-960
2005
Homo sapiens
brenda
Eriksson, S.; Munch-Petersen, B.; Johansson, K.; Eklund, H.
Structure and function of cellular deoxyribonucleoside kinases
Cell. Mol. Life Sci.
59
1327-1346
2002
Homo sapiens (Q16854)
brenda
Wang, L.; Eriksson, S.
Mitochondrial deoxyguanosine kinase mutations and mitochondrial DNA depletion syndrome
FEBS Lett.
554
319-322
2003
Homo sapiens
brenda
Piskur, J.; Sandrini, M.P.B.; Knecht, W.; Munch-Petersen, B.
Animal deoxyribonucleoside kinases: 'forward' and 'retrograde' evolution of their substrate specificity
FEBS Lett.
560
3-6
2004
Homo sapiens (Q16854)
brenda
Wang, L.; Limongelli, A.; Vila, M.R.; Carrara, F.; Zeviani, M.; Eriksson, S.
Molecular insight into mitochondrial DNA depletion syndrome in two patients with novel mutations in the deoxyguanosine kinase and thymidine kinase 2 genes
Mol. Genet. Metab.
84
75-82
2005
Homo sapiens
brenda
Johansson, K.; Ramaswamy, S.; Ljungcrantz, C.; Knecht, W.; Piskur, J.; Munch-Petersen, B.; Eriksson, S.; Eklund, H.
Structural basis for substrate specificities of cellular deoxyribonucleoside kinases
Nat. Struct. Biol.
8
616-620
2001
Homo sapiens (Q16854), Homo sapiens
brenda
Krawiec, K.; Kierdaszuk, B.; Kalinichenko, E.N.; Rubinova, E.B.; Mikhailopulo, I.A.; Eriksson, S.; Munch-Petersen, B.; Shugar, D.
Ability of adenosine-2'(3')-deoxy-3'(2')-triphosphates and related analogues to replace ATP as phosphate donor for all human and Drosphila melanogaster deoxyribonucleoside kinases
Nucleosides Nucleotides Nucleic Acids
22
1525-1529
2003
Homo sapiens
brenda
Al-Madhoun, A.S.; Eriksson, S.; Wang, Z.X.; Naimi, E.; Knaus, E.E.; Wiebe, L.I.
Phosphorylation of isocarbostyril- and difluorophenyl-nucleoside thymidine mimics by the human deoxynucleoside kinases
Nucleosides Nucleotides Nucleic Acids
23
1865-1874
2004
Homo sapiens
brenda
Van Rompay, A.R.; Johansson, M.; Karlsson, A.
Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases
Pharmacol. Ther.
100
119-139
2003
Homo sapiens (Q16854)
brenda
Fyrberg, A.; Albertioni, F.; Lotfi, K.
Cell cycle effect on the activity of deoxynucleoside analogue metabolising enzymes
Biochem. Biophys. Res. Commun.
357
847-853
2007
Homo sapiens
brenda
Mousson de Camaret, B.; Taanman, J.W.; Padet, S.; Chassagne, M.; Mayencon, M.; Clerc-Renaud, P.; Mandon, G.; Zabot, M.T.; Lachaux, A.; Bozon, D.
Kinetic properties of mutant deoxyguanosine kinase in a case of reversible hepatic mtDNA depletion
Biochem. J.
402
377-385
2007
Homo sapiens
brenda
Lotfi, K.; Karlsson, K.; Fyrberg, A.; Juliusson, G.; Jonsson, V.; Peterson, C.; Eriksson, S.; Albertioni, F.
The pattern of deoxycytidine- and deoxyguanosine kinase activity in relation to messenger RNA expression in blood cells from untreated patients with B-cell chronic lymphocytic leukemia
Biochem. Pharmacol.
71
882-890
2006
Homo sapiens
brenda
Franco, M.; Johansson, M.; Karlsson, A.
Depletion of mitochondrial DNA by down-regulation of deoxyguanosine kinase expression in non-proliferating HeLa cells
Exp. Cell Res.
313
2687-2694
2007
Homo sapiens
brenda
Sandrini, M.P.B.; Soederbom, F.; Mikkelsen, N.E.; Piskur, J.
Dictyostelium discoideum salvages purine deoxyribonucleosides by highly specific bacterial-like deoxyribonucleoside kinases
J. Mol. Biol.
369
653-664
2007
Dictyostelium discoideum (Q54UT2), Dictyostelium discoideum
brenda
Dimmock, D.P.; Zhang, Q.; Dionisi-Vici, C.; Carrozzo, R.; Shieh, J.; Tang, L.Y.; Truong, C.; Schmitt, E.; Sifry-Platt, M.; Lucioli, S.; Santorelli, F.M.; Ficicioglu, C.H.; Rodriguez, M.; Wierenga, K.; Enns, G.M.; Longo, N.; Lipson, M.H.; Vallance, H.; Craigen, W.J.; Scaglia, F.; Wong, L.J.
Clinical and molecular features of mitochondrial DNA depletion due to mutations in deoxyguanosine kinase
Hum. Mutat.
29
330-331
2008
Homo sapiens (Q16854), Homo sapiens
brenda
Dimmock, D.P.; Dunn, J.K.; Feigenbaum, A.; Rupar, A.; Horvath, R.; Freisinger, P.; Mousson de Camaret, B.; Wong, L.J.; Scaglia, F.
Abnormal neurological features predict poor survival and should preclude liver transplantation in patients with deoxyguanosine kinase deficiency
Liver Transpl.
14
1480-1485
2008
Homo sapiens
brenda
Saada, A.
Mitochondrial deoxyribonucleotide pools in deoxyguanosine kinase deficiency
Mol. Genet. Metab.
95
169-173
2008
Homo sapiens
brenda
Fyrberg, A.; Albertioni, F.; Lotfi, K.
RNAi depletion of deoxycytidine and deoxyguanosine kinase in human leukemic CEM cells
Nucleosides Nucleotides Nucleic Acids
27
712-719
2008
Homo sapiens
brenda
Pronicka, E.; Weglewska-Jurkiewicz, A.; Taybert, J.; Pronicki, M.; Szymanska-Debinska, T.; Karkucinska-Wieckowska, A.; Jakobkiewicz-Banecka, J.; Kowalski, P.; Piekutowska-Abramczuk, D.; Pajdowska, M.; Socha, P.; Sykut-Cegielska, J.; Wegrzyn, G.
Post mortem identification of deoxyguanosine kinase (DGUOK) gene mutations combined with impaired glucose homeostasis and iron overload features in four infants with severe progressive liver failure
J. Appl. Genet.
52
61-66
2011
Homo sapiens
brenda
Buchaklian, A.H.; Helbling, D.; Ware, S.M.; Dimmock, D.P.
Recessive deoxyguanosine kinase deficiency causes juvenile onset mitochondrial myopathy
Mol. Genet. Metab.
107
92-94
2012
Homo sapiens
brenda
Sun, R.; Eriksson, S.; Wang, L.
Zidovudine induces downregulation of mitochondrial deoxynucleoside kinases: implications for mitochondrial toxicity of antiviral nucleoside analogs
Antimicrob. Agents Chemother.
58
6758-6766
2014
Homo sapiens
brenda
Sun, R.; Eriksson, S.; Wang, L.
Down-regulation of mitochondrial thymidine kinase 2 and deoxyguanosine kinase by didanosine: implication for mitochondrial toxicities of anti-HIV nucleoside analogs
Biochem. Biophys. Res. Commun.
450
1021-1026
2014
Homo sapiens
brenda
Li, Y.; Ding, Q.; Ou, L.; Qian, Y.; Zhang, J.
One-pot process of 2-deoxyguanylic acid catalyzed by a multi-enzyme system
Biotechnol. Bioprocess Eng.
20
37-43
2015
Bacillus subtilis (P37530), Bacillus subtilis 168 (P37530)
-
brenda
Vilarinho, S.; Sari, S.; Yilmaz, G.; Stiegler, A.L.; Boggon, T.J.; Jain, D.; Akyol, G.; Dalgic, B.; Guenel, M.; Lifton, R.P.
Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension
Hepatology
63
1977-1986
2016
Homo sapiens (Q16854), Homo sapiens
brenda
Lin, S.; Huang, C.; Sun, J.; Bollt, O.; Wang, X.; Martine, E.; Kang, J.; Taylor, M.D.; Fang, B.; Singh, P.K.; Koomen, J.; Hao, J.; Yang, S.
The mitochondrial deoxyguanosine kinase is required for cancer cell stemness in lung adenocarcinoma
EMBO Mol. Med.
11
e10849
2019
Homo sapiens (Q16854)
brenda
Mutahir, Z.; Christiansen, L.S.; Clausen, A.R.; Berchtold, M.W.; Gojkovic, Z.; Munch-Petersen, B.; Knecht, W.; Piskur, J.
Gene duplications and losses among vertebrate deoxyribonucleoside kinases of the non-TK1 family
Nucleosides Nucleotides Nucleic Acids
35
677-690
2016
no activity in Gallus gallus, Xenopus laevis (Q6GPW6)
brenda
Fang, W.; Song, P.; Xie, X.; Wang, J.; Lu, Y.; Li, G.; Abuduxikuer, K.
A fatal case of mitochondrial DNA depletion syndrome with novel compound heterozygous variants in the deoxyguanosine kinase gene
Oncotarget
8
84309-84319
2017
Homo sapiens (Q16854), Homo sapiens
brenda